Table 2 : Eicosanoids in asthmatic patients at baseline and following histamine challenge.


  baseline challenge p-value

LTB4 48.40 35.57 0.22
[pg/mL] (33.28-55.28) (24.37-52.09)
LTB4 74.64 70.42 0.71
[pg/µg of PA] (62.88-94.13) (42.01-119.02)
CysLTs 5.44 4.53 0.21
[pg/mL] (4.52-7.68) (3.79-6.42)
CysLTs 9.55 9.33 0.33
[pg/µg of PA] (8.32-13.72) (6.99-11.45)
LTC4 1.71 1.14 0.04*
[pg/mL] (1.21-2.14) (0.76-1.53)
LTC4 2.62 2.05 0.10
[pg/µg of PA] (2.13-3.44) (1.19-3.42)
trans-LTC4 1.24 0.62 0.02*
[pg/mL] (0.74-2.49) (0.53-1.11)
trans-LTC4 2.23 1.62 0.03*
[pg/µg of PA] (1.47-3.71) (0.75-2.35)
LTD4 1.09 0.93 0.64
[pg/mL] (0.77-1.23) (0.72-1.23)
LTD4 1.80 1.45 0.71
[pg/µg of PA] (1.12-2.25) (1.21-2.45)
LTE4 2.86 2.23 0.31
[pg/mL] (1.93-4.18) (1.62-3.40)
LTE4 5.22 4.33 0.76
[pg/µg of PA] (3.49-6.74) (3.09-6.18)
PGE2 1.99 2.05 0.76
[pg/mL] (1.44-2.75) (1.45-2.72)
PGE2 3.29 4.11 0.29
[pg/µg of PA] (2.73-4.65) (3.32-5.18)
13,14-dihydro-15-keto-PGE2 3.49 3.83 0.67
[pg/mL] (2.72-4.88) (2.76-4.86)  
13,14-dihydro-15-keto-PGE2 5.03 6.34 0.59
[pg/µg of PA] (4.44-8.03) (4.77-9.60)  
tetranor-PGE-M 21.36 15.76 0.41
[pg/mL] (12.20-38.80) (8.80-23.77)  
tetranor-PGE-M 34.50 27.64 0.71
[pg/µg of PA] (25.82-49.50) (16.26-45.38)  
PGD2 1.57 1.40 0.67
[pg/mL] (1.29-1.77) (1.00-1.85)  
PGD2 2.12 2.09 0.24
[pg/µg of PA] (1.86-3.03) (1.94-3.49)  
13,14-dihydro-15-keto-PGD2 3.48 3.79 0.85
[pg/mL] (2.44-5.03) (2.44-4.90)  
13,14-dihydro-15-keto-PGD2 6.27 5.88 0.40
[pg/µg of PA] (4.23-7.44) (4.56-8.71)  
9a,11b-PGF2 0.17 0.11 0.14
[pg/mL] (GC-MS) (0.13-0.34) (0.09-0.26)  
9a,11b-PGF2 0.28 0.22 0.42
[pg/µg of PA] (GC-MS) (0.22-0.65) (0.16-0.53)  
15-deoxy-delta12,14-PGJ2 3.58 2.88 0.82
[pg/mL] (1.65-5.06) (2.34-4.98)  
15-deoxy-delta12,14-PGJ2 5.54 6.87 0.60
[pg/µg of PA] (3.90-8.60) (5.10-8.13)  

* statistical significance values are expressed as median with upper and lower quartile [25%-75% percentiles].
AIA: aspirin-induced asthma, ATA: aspirin-tolerant asthma, CysLTs: cysteinyl leukotrienes,
GC-MS: gas chromatography/mass spectrometry, LT: leukotriene, PA: palmitic acid, PG: prostaglandin.
p-values :
I-AIA vs ATA at baseline.
II–AIA at baseline vs AIA post challenge.
III–ATA at baseline vs ATA post challenge.

Kaszuba et al.Hypersensitivity  2013 1:4DOI : 10.7243/2052-594X-1-4